Provid Announces National Cancer Institute Contract
News Sep 30, 2005
Provid Pharmaceuticals Inc. has announced the award of a $750,000 phase II SBIR contract by the National Cancer Institute.
The NCI and Provid will collaborate on a number of oncology targets over the next two years.
Provid will apply its hypothesis-driven drug discovery chemistry to translate the assay hits into viable drug candidate leads for applications in cancer therapy.
These projects emerged from the efforts of the Developmental Therapeutics Program Screening Technologies Branch at NCI, where small molecule assay hits have been identified and are ready for medicinal chemistry validation and optimization.
Dr. Gary Olson, Provid CEO, discussed the contract, “We are excited about the expansion of Provid's role with the NCI to help discover drugs for cancer therapeutics, and with the opportunity to collaborate with the scientists who have uncovered the new research targets.”
“The program is a great opportunity for Provid, and we value the confidence that the NCI has placed in us.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE